Breast CA Risk Up With Recent Hormonal Contraceptive Use

Share this content:
Breast CA Risk Up With Recent Hormonal Contraceptive Use
Breast CA Risk Up With Recent Hormonal Contraceptive Use

THURSDAY, Dec. 7, 2017 (HealthDay News) -- Women who currently use or recently used contemporary hormonal contraceptives have increased risk of breast cancer, although the absolute increase is small, according to a study published in the Dec. 7 issue of the New England Journal of Medicine.

Lina S. Mørch, Ph.D., from the University of Copenhagen in Denmark, and colleagues examined the correlations between hormonal contraception use and the risk of invasive breast cancer in 1.8 million women from Denmark aged 15 to 49 years.

The researchers identified 11,517 cases of breast cancer during 19.6 million person-years of follow-up. The relative risk of breast cancer was 1.20 (95 percent confidence interval [CI], 1.14 to 1.26) among all current and recent users of hormonal contraception, compared with women who had never used hormonal contraception. Risk increased with duration of use from 1.09 (95 percent CI, 0.96 to 1.23) with less than one year to 1.38 (95 percent CI, 1.26 to 1.51) with greater than 10 years (P = 0.002). Women who had used hormonal contraceptives for five years or more had a higher risk of breast cancer after discontinuing hormonal contraception than women who had not used hormonal contraceptives.

"The overall absolute increase in breast cancers diagnosed among current and recent users of any hormonal contraceptive was 13 (95 percent CI, 10 to 16) per 100,000 person-years, or approximately one extra breast cancer for every 7,690 women using hormonal contraception for one year," the authors write.

Two authors disclosed financial ties to the Novo Nordisk Foundation, which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »